{
  "docId": "019de076-e431-717d-85d5-60fbb8c86744",
  "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 42,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The chart shows pharmacokinetic data across five dose cohorts, demonstrating that the 150mg dose consistently stays above the predicted CNS efficacy thresholds.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/24",
  "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
  "deckJsonHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json",
  "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.57,
        "y": 0.3
      },
      "kind": "chart",
      "text": "NVL-655 Pharmacokinetics at Steady State (Day 15)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25755507-96b3-48fa-8728-0432dbea1e38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.05,
        "y": 0.33
      },
      "kind": "list",
      "text": "Maintained steady state plasma levels at or above the target efficacy thresholds; Favorable tolerability; Early anti-tumor activity observed in ALK-positive NSCLC patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75bcc8c3-0091-4dc9-a3ad-c19887f13479",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "Selection of 150 mg QD as RP2D was based on the following considerations:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fed7139f-d432-4195-aec0-b2886f356821",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.57,
        "y": 0.74
      },
      "kind": "source-note",
      "text": "Pharmacokinetic data for 200 mg QD cohort are not shown due to immaturity. CNS, central nervous system; QD, once daily. Based on ≥ 100% tumor growth inhibition...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5b3bd90-0594-4c49-8ed7-c02948753617",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "RP2D of 150mg QD Met All Desired Clinical Characteristics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1653339-b5bb-407e-a9de-98a87a4c18d9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "7e5f7b10-93f2-4a79-8889-fa33847c6028",
      "evidence": "chart/line: NVL-655 Pharmacokinetics at Steady State (Day 15)",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "8d1e4a8c-f1ea-44b8-8b19-15615718998d",
      "evidence": "The slide presents clinical evidence (PK data and patient outcomes) to support a strategic decision (RP2D selection).",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 36,
      "from": 17,
      "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents traction and clinical trial data from slides 17 to 36",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}